Samsung Biologics Co.,Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was KRW 212,588.31 million compared to KRW 126,009.57 million a year ago. Net income was KRW 798,056.21 million compared to KRW 393,589.47 million a year ago.

Basic earnings per share from continuing operations was KRW 11,442 compared to KRW 5,949 a year ago. Diluted earnings per share from continuing operations was KRW 11,432 compared to KRW 5,949 a year ago. Basic earnings per share was KRW 11,442 compared to KRW 5,949 a year ago.

Diluted earnings per share was KRW 11,432.